Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7255213 | PMC |
| http://dx.doi.org/10.1016/S2352-3026(20)30176-9 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
EORTC consensus recommendations for the treatment of mycosis fungoides/Sézary syndrome - Update 2023.
Eur J Cancer
December 2023
Department of Dermatology and Venereology, University Hospital of St. Pölten, Karl Landsteiner University of Health Sciences, St. Pölten, Austria; Karl Landsteiner Institute of Dermatological Research, Department of Dermatology and Venereology, University Hospital of St. Pölten, St. Pölten, Austria.
On behalf of the EORTC Cutaneous Lymphoma Tumours Group (EORTC-CLTG) and following up on earlier versions published in 2006 and 2017 this document provides an updated standard for the treatment of mycosis fungoides and Sézary syndrome (MF/SS). It considers recent relevant publications and treatment options introduced into clinical practice after 2017. Consensus was established among the authors through a series of consecutive consultations in writing and a round of discussion.
View Article and Find Full Text PDF[Incidence and clinical significance of platelet transfusion refractoriness after allogeneic hematopoietic stem cell transplantation in patients with chronic myelomonocytic leukemia].
Zhonghua Xue Ye Xue Za Zhi
September 2022
Peking University People's Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Beijing 100044, China.
To retrospectively analyze the incidence and clinical significance of platelet transfusion refractoriness (PTR) after allogeneic hematopoietic stem cell transplantation (allo-HSCT) in patients with chronic myelomonocytic leukemia (CMML) . A cohort of 55 CMML patients received allo-HSCT at Peking University Institute of Hematology during 2004-2021 were retrospectively assessed. The incidence of PTR within 30 days after allo-HSCT was retrospectively analyzed, and the impact on clinical outcomes and bleeding event were compared between patients with platelet transfusion refractoriness (PTR) or effective platelet transfusion (EPT) .
View Article and Find Full Text PDFSuccessful treatment with HLA-matched peripheral hematopoietic stem cell transplantation for very severe hepatitis-associated aplastic anemia complicated with multidrug-resistant bacterial and fungal infections: A case report.
Front Pediatr
October 2022
Hemopoietic Stem Cell Transplantation Center, Fujian Provincial Key Laboratory on Hematology, Clinical Research Center for Hematological Malignancies of Fujian Province, Fujian Institute of Hematology, Department of Hematology, Fujian Medical University Union Hospital, Fuzhou, China.
Hepatitis-associated aplastic anemia (HAAA) is a life-threatening hematologic disorder characterized by bone marrow failure. Allogeneic hematopoietic stem cell transplantation (HSCT) is the first-line treatment for HAAA. Severe infection and complications in patients with very severe aplastic anemia are the challenges to the efficacy of HSCT.
View Article and Find Full Text PDFFollowing-up allogeneic transplantation recipients during the COVID-19 pandemic.
Lancet Haematol
August 2020
Hematology and Bone Marrow Transplantation Unit, IRCCS San Raffaele Scientific Institute, Milan, Italy; School of Medicine, Vita-Salute San Raffaele University, Milan, Italy.
[Clinical Study of Allogeneic Hematopoietic Stem Cell Transplantation for Relapsed or Refractory Peripheral T-Cell Lymphoma].
Zhongguo Shi Yan Xue Ye Xue Za Zhi
December 2019
Department of Hematology, Aerospace Center Hospital，Beijing 100049,
Objective: To explore the efficacy and safety of allogeneic hematopoietic stem cell transplantation (allo-HSCT) in the treatment of relapsed or refractory peripheral T-cell lymphoma(PTCL).
Methods: The clinical data of 6 patients with relapsed or refractory PTCL undergoing allo-HSCT from Sep. 2014 to Sep.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!